Jefferies upgrades this pharma inventory, citing missed ‘blockbuster’ drug alternatives
AstraZeneca has a sturdy pipeline of therapies past oncology that buyers should not ignore, in accordance with Jefferies. Analyst Peter Welford upgraded the inventory to purchase from maintain. He additionally elevated his worth goal on U.S.-listed shares to $80 from $66.50, suggesting almost 18% upside doubtlessly from Friday’s closing worth of $67.83. “We argue consensus is overlooking the potential alternative from late stage cardio & respiratory pipeline property, notably Airsupra, tozorakimab, and eplontersen,” Welford stated in a Monday word. The analyst stated these R & D property supply “vital upside optionality” and might drive earnings and gross sales roughly 8% above consensus estimates. He pointed to bronchial asthma remedy Airsupra as an missed “blockbuster rescue inhaler” that might generate roughly $1 billion extra in gross sales, backed by a proprietary doctor survey that indicated increased consciousness and higher market penetration. The inhaler, which is launching in 2024, is a “de-risked asset,” he stated. AstraZeneca’s tozorakimab drug for persistent obstructive pulmonary illness additionally appears underappreciated, with a possible to succeed in $4.5 billion in peak gross sales, in accordance with Jefferies. The agency additionally suggests as much as $3.5 billion in gross sales for AstraZeneca’s eplontersen , a drug geared toward treating hereditary transthyretin-mediated amyloid polyneuropathy. The pharmaceutical big can also be poised to be the frontrunner in breast most cancers remedies. AstraZeneca’s Enhertu remedy, which it’s collectively growing with Japan’s Daiichi Sankyo, is “quickly changing into a breast most cancers standard-of-care” and on monitor to succeed in $14 billion in gross sales, in accordance with Jefferies. One other one in all AstraZeneca’s breast most cancers therapies, additionally being developed with Daiichi Sankyo, got here out with constructive information Friday. Its experimental precision drug datopotamab deruxtecan demonstrated an enchancment in slowing the development of a standard kind of breast most cancers in a late-stage trial. The pharma inventory rose after the information. To make sure, Welford famous uncertainty for AstraZeneca in its upcoming lung most cancers information and its CEO Pascal Soriot’s plans to depart the corporate, amongst different draw back dangers. Shares of AstraZeneca have declined 5.2% to date this quarter and are up lower than 0.1% for the yr. The inventory rose greater than 1% within the premarket Monday, nonetheless. — CNBC’s Michael Bloom contributed to this report.
